Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 256Breast Neoplasms 173Neoplasms 169Colorectal Neoplasms 155Neoplasm Metastasis 126Melanoma 120Recurrence 118Prostatic Neoplasms 118Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 115Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 95Stomach Neoplasms 92Squamous Cell Carcinoma of Head and Neck 86Triple Negative Breast Neoplasms 85Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Carcinoma, Renal Cell 64Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lip Neoplasms × 1 year × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡